Capitalizing on Market Overreactions and Bargain Issues

Key Insight

Significant opportunities for enterprising investors arise when the market overreacts to alarming setbacks for a company or widespread economic chaos, such as during the 2008-2009 financial crisis or the 2020 Covid pandemic. Paradoxically, when perceived risk increases, actual risk can decrease due to lower prices, which creates potential for superior future returns. Such market overreactions distract from the fundamental question of a company's long-term ability to generate cash.

Examples include W. W. Grainger, Inc., whose stock plunged nearly 40% in 2017 after announcing price cuts due to Amazon.com competition. However, the business fundamentals remained strong, with sales rising 8% and net income climbing 33% by 2018. Over five years, the stock gained an annual average of 22.2%, outperforming the S&P 500 by 6.8 percentage points annually. Similarly, Fair Isaac Corp.'s shares fell 76% from 2006 to 2009, reaching valuations of one times sales, slightly over one times book value, four times cash flow, and nine times earnings. Despite a 23% sales shrinkage, net cash flow from operations rose over 10%, leading to a 2400% stock gain over the next decade.

A particularly compelling type of 'bargain issue' is a company trading below its net current asset value (NCAV). This means the stock price is less than its cash, receivables, inventories, and other liquid assets, minus all liabilities, effectively valuing fixed assets at zero. This 'ridiculously simple' approach, proven successful for over 30 years in prior experience, was prevalent during market declines like 1970. In late 2023, about 2.5% (80 out of 3100) of regularly traded U.S. stocks met this criterion, mostly small biotechnology or pharmaceutical firms. Investing in a diversified group of such companies, even if some fail, can yield significant profits if others succeed or are acquired, as exemplified by Burton-Dixie Corp. which returned 165% in three and a half years.